Impact of the COVID-19 Pandemic on Breast Imaging: An Analysis of the National Mammography Database.

PURPOSE: The aim of this study was to quantify the initial decline and subsequent rebound in breast cancer screening metrics throughout the coronavirus disease 2019 (COVID-19) pandemic. METHODS: Screening and diagnostic mammographic examinations, biopsies performed, and cancer diagnoses were extracted from the ACR National Mammography Database from March 1, 2019, through May 31, 2021. Patient (race and age) and facility (regional location, community type, and facility type) demographics were collected. Three time periods were used for analysis: pre-COVID-19 (March 1, 2019, to May 31, 2019), peak COVID-19 (March 1, 2020, to May 31, 2020), and COVID-19 recovery (March 1, 2021, to May 31, 2021). Analysis was performed at the facility level and overall between time periods. RESULTS: In total, 5,633,783 screening mammographic studies, 1,282,374 diagnostic mammographic studies, 231,390 biopsies, and 69,657 cancer diagnoses were analyzed. All peak COVID-19 metrics were less than pre-COVID-19 volumes: 36.3% of pre-COVID-19 for screening mammography, 57.9% for diagnostic mammography, 47.3% for biopsies, and 48.7% for cancer diagnoses. There was some rebound during COVID-19 recovery as a percentage of pre-COVID-19 volumes: 85.3% of pre-COVID-19 for screening mammography, 97.8% for diagnostic mammography, 91.5% for biopsies, and 92.0% for cancer diagnoses. Across various metrics, there was a disproportionate negative impact on older women, Asian women, facilities in the Northeast, and facilities affiliated with academic medical centers. CONCLUSIONS: COVID-19 had the greatest impact on screening mammography volumes, which have not returned to pre-COVID-19 levels. Cancer diagnoses declined significantly in the acute phase and have not fully rebounded, emphasizing the need to increase outreach efforts directed at specific patient population and facility types.

CT Volumes from 2,398 Radiology Practices in the United States: A Real-Time Indicator of the Effect of COVID-19 on Routine Care, January to September 2020.

PURPOSE: To determine the effect of coronavirus disease 2019 (COVID-19) on CT volumes in the United States during and after the first wave of the pandemic. METHODS: CT volumes from 2,398 US radiology practices participating in the ACR Dose Index Registry from January 1, 2020, to September 30, 2020, were analyzed. Data were compared to projected CT volumes using 2019 normative data and analyzed with respect to time since government orders, population-normalized positive COVID-19 tests, and attributed deaths. Data were stratified by state population density, unemployment status, and race. RESULTS: There were 16,198,830 CT examinations (2,398 practices). Volume nadir occurred an average of 32 days after each state-of-emergency declaration and 12 days after each stay-at-home order. At nadir, the projected volume loss was 38,043 CTs per day (of 71,626 CTs per day; 53% reduction). Over the entire study period, there were 3,689,874 fewer CT examinations performed than predicted (of 18,947,969; 19% reduction). There was less reduction in states with smaller population density (15% [169,378 of 1,142,247; quartile 1] versus 21% [1,894,152 of 9,140,689; quartile 4]) and less reduction in states with a lower insured unemployed proportion (13% [279,331 of 2,071,251; quartile 1] versus 23% [1,753,521 of 7,496,443; quartile 4]). By September 30, CT volume had returned to 84% (59,856 of 71,321) of predicted; recovery of CT volume occurred as positive COVID-19 tests rose and deaths were in decline. CONCLUSION: COVID-19 substantially reduced US CT volume, reflecting delayed and deferred care, especially in states with greater unemployment. Partial volume recovery occurred despite rising positive COVID-19 tests.